CTB
MBRX icon

Country Trust Bank’s Moleculin Biotech MBRX Stock Holding History

Country Trust Bank’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1
Closed -$2K – 297
2019
Q4 		$2K Hold
1
– – ﹤0.01% 253
2019
Q3 		$3K Hold
1
– – ﹤0.01% 238
2019
Q2 		$3K Buy
+1
New +$2.72K ﹤0.01% 233

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Country Trust Bank's MBRX Position: Q1 2020 in Review

Country Trust Bank sold out of Moleculin Biotech (MBRX) in Q1 2020, closing a stake of 1 share — an estimated $2K sold.

Country Trust Bank first reported a position in MBRX in Q2 2019 and held it in 3 quarters. The position peaked at $3K in Q3 2019. 17 funds tracked by Wall St. Rank hold MBRX as of Q1 2020.

  • Country Trust Bank reported no remaining Moleculin Biotech position as of Q1 2020 after selling out during the quarter.
  • Country Trust Bank sold 1 Moleculin Biotech share in Q1 2020, an estimated $2K.
  • Country Trust Bank first reported a position in Moleculin Biotech in Q2 2019 and held it in 3 quarters.
  • Country Trust Bank's Moleculin Biotech position peaked at $3K in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2020.

Based on Country Trust Bank's 13F filing for Q1 2020, filed 17 Apr 2020.